14 results about "Catecholaminergic" patented technology

The present application discloses a method for detecting catecholamines, a detection probe, and a detection sensor. The detection method is to detect the fluorescence value of ferroferric oxide quantum dots at an excitation wavelength of 280 to 350 nm and / or the ultraviolet absorption value at a wavelength of 220 to 350 nm under the conditions of adding a buffer and a target analyte. The present technical solution has a fluorescence and ultraviolet dual signal detection mode, making the detection results more accurate and reliable. The present technical solution has the advantages of faster response speed, good selectivity, high sensitivity, and strong anti-interference ability. It has good application potential for detecting catecholamines in serum samples, and can semi-quantitatively and visually detect EP, NEP, and DA, and has great promotion and application value.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present application relates to the field of clinical laboratory medicine technology, in particular to a neuroblastoma and catecholamine-related tumor diagnosis kit and its application. The kit contains key components for detecting high vanillylmandelic acid and vanillylmandelic acid in urine, including isotope internal standard, specific chromatographic column, optimized mobile phase and sample pretreatment material. The detection method using the kit optimizes the collection, preservation and pretreatment process of instant urine samples, and combines the liquid chromatography-tandem mass spectrometry (LC-MS / MS) analysis conditions designed for low concentration and complex matrix samples to realize the rapid and accurate quantification of trace HVA and VMA in urine. It overcomes the shortcomings of traditional 24-hour urine detection method such as large trauma, long cycle and poor accuracy, and provides an efficient and reliable solution for non-invasive, early diagnosis and postoperative efficacy monitoring of neuroblastoma and other catecholamine-related tumors, which has important clinical application value.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a method for detecting catecholamines in blood or urine, comprising the following steps: (1) adding 0.1 to 20 mg of a magnetic solid-phase extractant to each milliliter of a sample to be tested, mixing, magnetically separating, and removing the liquid; adding a washing solution, mixing, magnetically separating, and removing the liquid; adding an eluent for elution, mixing, magnetically separating, and collecting the eluate to obtain a test solution; (2) detecting the catecholamine content in the test solution by liquid chromatography and tandem mass spectrometry; the catecholamine is selected from any one of norepinephrine, epinephrine, dopamine, 3-methoxydopamine, metanephrine, and normetanephrine, or a combination thereof; the magnetic solid-phase extractant comprises a magnetic core of ferrosoferric oxide, a middle-layer structure of silica wrapping the magnetic core, and an outer-layer mesoporous structure, wherein the outer-layer mesoporous structure is selected from any one of polystyrene and polystyrene divinylbenzene, or a combination thereof. The present invention solves the problems in the prior art of being difficult to accurately determine the catecholamine content in human serum, and most of the problems are long analysis time, complex sample pretreatment, few types of determination, and inability to simultaneously determine multiple contents. The present invention has the characteristics of good stability, high accuracy and sensitivity, strong specificity, high recovery rate, simple and controllable operation, and fast analysis speed.

The invention provides a method for synchronously detecting five catecholamines in urine based on derivatization nano electrospray ionization mass spectrometry. The method solves the technical problems that an existing detection method is tedious in step, long in detection time, limited in sensitivity and the like. The five kinds of catecholamine are respectively dopamine, noradrenaline, noradrenaline, noradrenaline and 3-methoxytyramine; the method comprises the following steps: S1, filtering a urine sample to be detected by a microfiltration membrane; s2, carrying out derivatization treatment on a filtrate filtered by the microfiltration membrane by adopting dansyl chloride to obtain a mixed solution containing a to-be-detected derivatization product; s3, carrying out liquid-liquid extraction on the mixed solution containing the to-be-detected derivatization product to obtain an organic phase; s4, blow-drying the organic phase, and re-dissolving with a re-dissolving solvent to obtain a re-dissolving solution; s5, directly detecting the redissolved solution by using a nano electrospray ion source in a mass spectrum, carrying out qualitative analysis by comparing secondary mass spectrum characteristic ion peaks, and carrying out quantitative analysis by using a standard curve external standard method; the method can be widely applied to the technical field of biological analysis and detection.

The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like.The present invention relates to a compound represented by the formula (I):wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

The application discloses a method for preparing a mesoporous hollow nanoscale spherical structure adsorbent based on emulsion and micelle assembly and application of the adsorbent in uranium extraction. The mesoporous hollow nanoscale spherical structure material is combined with an amidoxime group, and a green and efficient uranium extraction adsorbent is prepared through a soft template method, self-polymerization of dopamine and amidoximation reaction. First, a nonionic surfactant, dopamine hydrochloride and an expanding agent 1,3,5-trimethylbenzene are used to form an emulsion / micelle system, ammonia is added after stirring to initiate the oxidative self-polymerization reaction of dopamine, and a mesoporous hollow nanoscale spherical catecholamine polymer MHS is prepared; then, a functional monomer 2-amino-3,5-divinylbenzonitrile is grafted to the MHS under the initiation of AIBN, and a cyan-amino bifunctionalized nanosphere CN-NH2-MHS is obtained; finally, the CN-NH2-MHS is chemically modified by hydroxylamine hydrochloride, the cyan group is converted into an amidoxime AO group, and thus an amidoxime-amino synergistically functionalized high-stability mesoporous hollow nanoscale spherical structure adsorbent AO-NH2-MHS is prepared.

The invention relates to methods for improving treatment outcomes in patients undergoing ultrafiltration. Ultrafiltration during hemodialysis or fluid removal can induce sympathetic nervous system activation, hypovolemia, catecholamine surge, and widespread microvascular ischemia, leading to cardiac stunning, dialysis intolerance, and organ injury. Disclosed herein are methods of administering a therapeutically effective amount of one or more receptor agonists of the renin-angiotensin system (RAS), including angiotensin II, angiotensin III, angiotensin IV, angiotensin 1-7, and / or prorenin receptor (PRR) agonists, to maintain capillary perfusion and prevent ischemia. The methods reduce risk or incidence of catecholamine surge, intradialytic hypotension, cardiac dysfunction, and muscle cramps, and also prevent or minimize systemic ischemic injury to the brain, heart, kidneys, liver, and skeletal muscle. By preserving systemic microvascular blood flow, the disclosed methods mitigate or prevent dialysis-associated heart disease as well as neurocognitive impairment, including white matter injury, memory decline, and executive dysfunction. These approaches enable improved hemodynamic stability, achieving ultrafiltration targets without the need to adjust treatment goals, reducing the necessity for fluid bolus administration, aiding in reaching dry weight, achievement of dry weight goals, minimizing the occurrence and severity of skeletal muscle cramps, and reduced long-term cardiovascular and neurological complications in patients receiving ultrafiltration therapy.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The invention discloses a method for simultaneously determining the contents of 12 catecholamines and metabolites thereof through liquid chromatography-mass spectrometry, and the 12 metabolites comprise epinephrine, noradrenaline, dopamine, methoxyepinephrine, methoxynoradrenaline, 3-methoxytyramine, vanillylmandelic acid, homovanillic acid, 3, 3 '-dihydroxy-2, 3'-dihydroxy-2, 3 '-dihydroxy-2, 3'-dihydroxy-2, 3 '-dihydroxy-2, 3'-dihydroxy-2, 3 '-dihydroxy-2, 3'-dihydroxy-2, 3 '-dihydroxy-2, 3'-dihydroxy-2, 3 '-dihydroxy-2, 3' the components are selected from the group consisting of 2, 4-dihydroxyphenylacetic acid, 3-methoxyl-4-hydroxy-phenyl glycol, 5-hydroxyindole-3-acetic acid and 5-hydroxytryptamine. The method comprises the following steps: preparing a standard substance, a quality control substance and a sample, adding an internal standard sample for deproteinization treatment, derivatizing the sample, extracting a derivative product, blow-drying an extracting solvent, redissolving and detecting on a machine. The method can be used for simultaneously determining 12 catecholamines and metabolites thereof, and has the advantages of high sensitivity, simple steps and high recovery rate.

The present invention provides a means for effective treatment for dependence on a drug, or the like. More specifically, the present invention relates to a pharmaceutical composition used to inhibit the release of catecholamines from catecholaminergic neurons in a subject, said composition including a tyrosine hydroxylase (TH) inhibitor.

The present invention relates to a compound of formula (I), as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.